Actively Recruiting
New Imaging Biomarkers Predictive of MA Progression
Led by Poitiers University Hospital · Updated on 2024-12-10
80
Participants Needed
1
Research Sites
223 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death. Ultra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.
CONDITIONS
Official Title
New Imaging Biomarkers Predictive of MA Progression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- French-speaking patients aged 60 to 90 years
- Diagnosis of Alzheimer's disease confirmed by a memory specialist
- Imaging with MRI prescribed as part of usual diagnostic process
- Evidence of verbal episodic memory storage disorder with specific test scores
- Possible impairment in executive and instrumental functions
- Mini-Mental State Examination (MMSE) score of 18 or higher
- Written informed consent obtained
- Progressive cognitive decline for at least 6 months
You will not qualify if you...
- Patients who are partially or completely illiterate and unable to read or write
- Patients with absolute contraindications to 7 Tesla MRI
- Patients with severe, uncontrolled psychiatric conditions
- Patients with non-degenerative neurological diseases such as stroke or multiple sclerosis
- Patients with tumors, inflammatory diseases, or vascular brain changes seen on MRI with Fazekas score greater than 3
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu Poitiers
Poitiers, France
Actively Recruiting
Research Team
A
Adrien JULIAN, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here